JPMorgan upgraded CytomX Therapeutics (CTMX) to Overweight from Neutral with a price target of $12, up from $7.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics price target raised to $12 from $10 at Oppenheimer
- Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform
- Options Volatility and Implied Earnings Moves Today, March 16, 2026
- CytomX Therapeutics announces Phase 1 expansion data on varsetatug masetecan
- CytomX Therapeutics reports Q4 EPS (22c), consensus (9c)